2 results
Approved WMORecruiting
To assess which treatment leads to the best patient outcome on the short term (1 year) and the long term (5 years)
Approved WMORecruiting
Primary Objectives 1. To evaluate the efficacy of clazakizumab in preventing all-cause composite allograft loss (including death) due to CABMR.2. To evaluate the efficacy of clazakizumab in slowing/preventing the progressive loss of kidney function…